Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
June 28th, 2018
Infectious pneumonia is among the most common infections in human. An appropriate in vivo model is critical for understanding disease pathogenesis and testing the efficacy of novel therapeutics. With this murine oropharyngeal aspiration pneumonia model, one can examine the pathogenesis and new treatments against these deadly infections.
This method can help answer key questions in the field of antibiotic resistance about novel therapeutics with a treatment of ventilator-associated pneumonia. The main advantage of this technique is that it accurately replicates clinical infection in a quick and easily reproducible manner. To inoculate the mice, hang the first anesthetized animal by its top incisors on a strong thin string.
Secure it to a fixed object above the operating surface, at a height approximately twice the mouse's body length. Use sterile blunt-handed forceps to gently pull out the tongue, and transfer the tongue to sterile, gloved fingers to allow access to the oral pharynx. Depress the plunger of a micro pipette to the first stop to place 50 microliters of the inoculum into the oral pharynx, until the mouse inhales the bacterial suspension, by reflexive aspiration.
The mouse will stop breathing for a few seconds when the inoculum is placed in the oral pharynx, and eventually reflexive aspiration will cause the bacterial suspension to be inhaled, indicative by the distinctive crackling noise of liquid entering the lungs. Then return the animal to its cage, with monitoring, until full recumbency. At the appropriate experimental endpoint, cut the trachea, pulmonary artery, and pulmonary vein, to allow removal of the lung tissue.
For histopathological analysis of the disease progression, place the lungs into a specimen mold. And fill the mold with optimal cutting temperature compound, until the tissue is completely submerged. Then freeze the samples at minus 80 degrees Celsius, until their sectioning and analysis.
To estimate the bacterial burden, transfer the harvested lung tissue to a 50 milliliter conical vial, and determine its mass with an analytical balance. Then transfer five milliliters of sterile PBS to the vial. Homogenize the lung tissue with a tissue homogenizer.
And perform serial dilutions in the homogenate and sterile PBS, to achieve approximately 1000 colony forming units, or CFU, per millimeter, based on the expected bacterial burden in the infected lungs. Plate 100 microliters of each dilution onto individual tryptic soy agar plates. And use glass beads to evenly distribute the homogenates.
Then store the plates in a humidified, 37 degree Celsius incubator over night. Before calculating the number of colony forming units per dilution. It is necessary to infect the mice with various inoculum concentrations, to determine the LD 100.
Under these representative experimental conditions, two times 10 to the eighth CFU per mouse was too high. Five times 10 to the seventh and two times 10 to the seventh, were too low. And one times 10 to the eighth was just right Hematoxylin and ee-ah-zin staining of lung sections before and 24 hours after oral pharyngeal aspiration of the bacterial species commonly encountered in ventilator-associated pneumonia in humans, typically results in substantial alveolar inflammation.
While attempting this procedure, it's important to remember the inoculum must be prepared and atomy surd identically from experiment to experiment to obtain reproducible results. After watching this video, you should have a good understanding of how to recapitulate ventilator-associated pneumonia using a mouse model.
View the full transcript and gain access to thousands of scientific videos
Overview
This article discusses a murine oropharyngeal aspiration pneumonia model that is essential for studying infectious pneumonia. It allows researchers to investigate disease pathogenesis and evaluate new therapeutic approaches effectively.
Key Study Components
Area of Science
- Infectious diseases
- Pneumonia research
- Antibiotic resistance
Background
- Infectious pneumonia is a prevalent human infection.
- Understanding its pathogenesis is crucial for developing treatments.
- In vivo models are necessary for accurate disease study.
- This model mimics clinical infection scenarios effectively.
Purpose of Study
- To explore the pathogenesis of infectious pneumonia.
- To test the efficacy of novel therapeutics.
- To address key questions regarding antibiotic resistance.
Methods Used
- Murine model for oropharyngeal aspiration pneumonia.
- Inoculation of mice with bacterial suspension.
- Use of anesthetized mice for accurate replication of infection.
- Quick and reproducible technique for experimental consistency.
Main Results
- The model successfully replicates clinical infection.
- Facilitates the study of novel therapeutics for pneumonia.
- Provides insights into antibiotic resistance mechanisms.
- Demonstrates ease of use and reproducibility in experiments.
Conclusions
- The murine model is effective for studying pneumonia.
- It aids in the development of new treatment strategies.
- Contributes to understanding antibiotic resistance in infections.
Frequently Asked Questions
Executive Industry Relevance
This murine oropharyngeal aspiration model provides a clinically relevant system for studying bacterial pneumonia pathogenesis, directly supporting target validation and mechanistic de-risking in antibiotic development. By replicating healthcare-acquired infection routes, it enables predictive confidence in therapeutic efficacy and reduces biological uncertainty in preclinical pipelines. The model’s reproducibility and quantitative outputs facilitate cross-functional alignment in discovery workflows.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates therapeutic hypotheses by enabling pathogenesis examination of pneumonia-causing pathogens.
- Operational Value: Supports functional target validation through reproducible bacterial burden quantification via CFU assays.
- Predictive Value: Enhances portfolio triage by modeling droplet-mediated infection typical of ventilator-associated pneumonia.
Screening & Assay Development
- Scientific Value: Prepares validated lung tissue for downstream analysis, including histopathological and microbiological readouts.
- Operational Value: Standardizes inoculum delivery via reflexive aspiration, improving assay consistency across experiments.
- Scalability: Enables serial dilution and plating workflows for dose-response characterization of novel therapeutics.
Translational & Preclinical Research
- Translational Continuity: Mirrors clinical droplet transmission in healthcare settings, strengthening disease relevance.
- Mechanistic De-risking: Captures alveolar inflammation and bacterial load dynamics predictive of human infection progression.
- Preclinical Alignment: Supports risk-adjusted advancement decisions by linking inoculum concentration to LD100 determination.
Pipeline & Workflow Integration
The model integrates into discovery workflows from early target validation through preclinical efficacy testing, particularly for antibiotic candidates targeting hospital-acquired bacterial pneumonia.
- Discovery Biology: Enables hypothesis testing of pathogen virulence and host response through controlled oropharyngeal aspiration.
- Screening: Generates quantitative CFU data from homogenized lung tissue, supporting compound evaluation in infection models.
- Analytics: Provides histopathological and bacteriological outputs that allow comparison of treatment effects across conditions.
- Translational Research: Connects to preclinical validation by modeling pneumonia progression relevant to ventilator-associated scenarios.
- Enterprise Reuse: Establishes a reusable infectious disease platform for iterative therapeutic screening and resistance mechanism studies.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity by accurately replicating clinical infection routes and pneumonia pathogenesis.
- Operational Value: Ensures reproducibility through standardized anesthesia, inoculation, and tissue processing protocols.
- Strategic Value: Improves go/no-go decisions by linking bacterial burden to therapeutic response in a clinically reflective model.
- Portfolio Impact: Enables risk-adjusted prioritization of antibiotic candidates based on efficacy in a healthcare-acquired pneumonia model.
Implementation Considerations
- Requires expertise in murine handling, anesthesia, and oropharyngeal inoculation techniques.
- Dependent on sterile microbiological infrastructure for CFU quantification and tissue homogenization.
- Necessitates cross-team standardization of inoculum preparation and LD100 determination for reproducible results.
- Adaptation considerations include pathogen-specific virulence and inoculum volume adjustments across bacterial strains.
- Practical limitations include the need for precise technical execution to avoid off-target deposition and ensure reflexive aspiration.
